Fatty Liver Disease Explained: Causes, Risks, and Prevention

Fatty liver disease develops when more fat accumulates in the liver than the organ can safely process. In many people, this is closely connected to insulin resistance, type 2 diabetes, excess abdominal fat, abnormal blood lipids, or high blood pressure. Alcohol, certain medications, rapid weight loss, malnutrition, inherited disorders, and other conditions can also contribute.

The condition is often discovered before symptoms appear. While fat alone may not immediately impair liver function, some people develop inflammation and progressive scarring that can eventually lead to cirrhosis or liver cancer. Understanding fatty liver disease therefore means looking beyond a single liver-enzyme result and considering metabolic health, alcohol exposure, medications, family history, and the degree of existing liver damage.

For a broader explanation of how the liver processes nutrients and protects the body, see Liver and Kidney Health: How the Body Filters, Balances, and Protects Itself.

What Fatty Liver Disease Means

The liver normally contains some fat. Fatty liver disease, more formally called steatotic liver disease, occurs when excess fat collects within liver cells. “Fatty liver” is therefore a description of what is happening in the organ, not a complete diagnosis of why it is happening or how severe it has become.

Several pathways can lead to liver-fat accumulation. In metabolic disease, the liver may receive more fatty acids from the bloodstream, manufacture more fat from excess energy, or become less efficient at using and exporting fat. Alcohol can also change liver metabolism and promote fat accumulation. Certain medications, toxins, genetic conditions, and nutritional problems may produce similar findings through different mechanisms.

This distinction matters because treatment should address the underlying cause. A person whose liver fat is primarily associated with type 2 diabetes needs a different risk-management plan from someone whose condition is mainly driven by alcohol, a medication, or a rare inherited disorder.

Understanding the New Terminology

Medical terminology for fatty liver disease changed after a multinational consensus process announced in 2023. Steatotic liver disease, or SLD, is now the broad umbrella term for conditions involving excess liver fat.

The main categories include:

• Metabolic dysfunction-associated steatotic liver disease, or MASLD: Liver fat accompanied by at least one defined cardiometabolic risk factor.
• Metabolic dysfunction-associated steatohepatitis, or MASH: The inflammatory form of MASLD, in which fat is accompanied by liver-cell injury and inflammation.
• Alcohol-associated liver disease: Liver injury in which alcohol is a primary cause.
• MetALD: A category recognizing that metabolic dysfunction and clinically meaningful alcohol exposure may coexist.
• Other forms of steatotic liver disease: These include medication-related, genetic, nutritional, and otherwise unexplained causes.

Older terms remain common in medical records and patient information. MASLD was previously called nonalcoholic fatty liver disease, or NAFLD, while MASH was called nonalcoholic steatohepatitis, or NASH. The newer terminology emphasizes the metabolic drivers of disease and recognizes that metabolic and alcohol-related factors can overlap.

What Causes Metabolic Fatty Liver Disease?

MASLD is not caused by eating one particular food or by consuming dietary fat alone. It usually develops through a combination of metabolic, behavioral, genetic, and environmental influences.

Insulin Resistance

Insulin helps move glucose from the blood into cells and regulates how the body stores and releases energy. When tissues become less responsive to insulin, the body may release more fatty acids into circulation and the liver may produce more fat. Insulin resistance is closely associated with prediabetes, type 2 diabetes, abdominal obesity, high triglycerides, and other features of metabolic dysfunction.

A person can have insulin resistance for years before diabetes is diagnosed. Liver-fat accumulation may therefore be one sign of a wider metabolic problem rather than an isolated liver condition.

Excess Abdominal or Visceral Fat

Fat stored around abdominal organs is metabolically active. It can release fatty acids and signaling compounds that contribute to insulin resistance and inflammation. Although overweight and obesity increase the likelihood of MASLD, body weight alone does not determine risk. People without obesity can also develop the condition, particularly when they have diabetes, abnormal blood lipids, genetic susceptibility, or excess visceral fat.

Weight-related language should not be used to assign blame. Body weight is influenced by biology, medications, health conditions, environment, access to food, sleep, stress, and other factors. The clinical goal is to identify modifiable risks without reducing the condition to willpower.

Type 2 Diabetes and Prediabetes

Type 2 diabetes is one of the strongest clinical signals that a person may have MASLD or be at risk of progressive liver disease. High blood sugar and insulin resistance can promote liver-fat accumulation, while liver dysfunction may further complicate glucose and lipid regulation. Because these conditions reinforce one another, diabetes care and liver care should be coordinated rather than treated as unrelated concerns.

Abnormal Cholesterol and Triglycerides

High triglycerides, low HDL cholesterol, and other lipid abnormalities commonly occur alongside MASLD. They also contribute to cardiovascular risk, which remains an important part of the overall health picture. Treating lipid disorders is therefore not only about changing liver tests; it is also about protecting the heart and blood vessels.

Diet and Physical Inactivity

An eating pattern that regularly supplies more energy than the body needs can contribute to weight gain, insulin resistance, and liver-fat accumulation. Sugar-sweetened drinks and foods containing large amounts of added simple sugars may be especially easy to consume in excess because they provide substantial energy with limited fullness. Low physical activity can further reduce metabolic flexibility and insulin sensitivity.

No single food causes every case of fatty liver disease. The overall pattern, portion sizes, frequency, metabolic context, and sustainability of the diet matter more than labeling individual foods as toxic.

Other Causes of Fatty Liver

Not all liver fat should be classified as MASLD.

Alcohol Exposure

Alcohol is processed primarily by the liver. Repeated high exposure can alter fat metabolism, promote inflammation, and damage liver cells. The effect of alcohol varies according to dose, drinking pattern, sex, genetics, nutrition, medications, and existing liver disease. Metabolic risk and alcohol exposure may also operate together rather than as mutually exclusive causes.

People frequently underestimate serving sizes or the alcohol content of mixed drinks. A careful history is important because imaging cannot reliably determine how much liver fat came from alcohol versus metabolic dysfunction.

Medications

Some medications can contribute to liver-fat accumulation or liver injury. Examples may include certain corticosteroids, estrogen-containing treatments, HIV therapies, cancer medicines, and other drugs. The risk depends on the specific medication, dose, duration, and the patient’s underlying health.

A suspected medication effect should be reviewed by a clinician. Abruptly stopping a necessary prescription can be more dangerous than continuing it while an appropriate evaluation is completed.

Rapid Weight Loss and Malnutrition

Severe calorie restriction, malnutrition, and very rapid weight loss can worsen liver inflammation or cause fat to accumulate in the liver. This is one reason that gradual, adequately nourished weight reduction is preferred over crash diets and prolonged unsupervised fasting.

Genetic and Uncommon Conditions

Inherited variations can influence how the liver stores and processes fat and may help explain why people with similar lifestyles develop different levels of disease. Less common causes include lipodystrophy, Wilson disease, hypobetalipoproteinemia, and other disorders affecting fat storage or metabolism.

These possibilities become especially important when liver disease appears at a young age, progresses unexpectedly, occurs without typical metabolic risks, or follows a strong family pattern.

Who Is Most at Risk?

Fatty liver disease should be considered more closely in people with one or more of the following:

• Type 2 diabetes or prediabetes
• Abdominal obesity or increasing waist circumference
• High triglycerides or other cholesterol abnormalities
• High blood pressure
• Metabolic syndrome
• A family history of fatty liver disease, cirrhosis, or liver cancer
• Regular or heavy alcohol exposure
• Use of medications associated with liver fat or injury
• Persistently abnormal liver tests
• Imaging that suggests excess liver fat
• Another condition associated with insulin resistance

The presence of several risk factors raises concern, but their absence does not completely rule out disease. Evaluation should be based on the full clinical picture rather than appearance or body size alone.

How Fatty Liver Disease Can Progress

Fatty liver disease exists along a spectrum.

Steatosis

At the earliest stage, excess fat is present but there may be little inflammation or liver-cell injury. This is sometimes called simple steatosis. Many people remain at this stage, particularly when metabolic risks are addressed.

Steatohepatitis

In MASH, fat accumulation is accompanied by inflammation and injury to liver cells. This inflammatory state increases the chance that scar tissue will form. MASH cannot always be distinguished from simple steatosis using routine liver enzymes or a standard ultrasound alone.

Fibrosis

Fibrosis is scar tissue produced as the liver repeatedly repairs injury. Early fibrosis may be limited, while more advanced fibrosis can bridge different areas of the liver. The amount of fibrosis is a central factor in estimating the likelihood of future liver complications.

Cirrhosis

Cirrhosis is advanced, widespread scarring that changes the liver’s structure and may impair blood flow and function. It can lead to fluid accumulation, internal bleeding, confusion, infection risk, liver failure, and liver cancer. Not everyone with fatty liver disease reaches this stage, and progression often occurs over many years.

Disease progression is not necessarily one-directional. Liver fat and inflammation may improve when the underlying drivers are treated. Earlier fibrosis may also improve in some people, although advanced cirrhosis is more difficult to reverse.

Why Fatty Liver Disease Is Often Missed

MASLD is commonly described as a silent disease because many people have few or no symptoms. When symptoms occur, they may include fatigue or vague discomfort in the upper-right abdomen, neither of which is specific to liver disease. Even some people with advanced disease may not initially recognize symptoms.

Fatty liver may be discovered after:

• Routine blood tests show elevated ALT or AST
• An ultrasound, CT scan, or MRI is performed for another reason
• Diabetes or cardiovascular risk assessment prompts liver screening
• A clinician investigates abdominal symptoms
• Platelet counts or other laboratory trends suggest possible fibrosis

Normal liver enzymes do not necessarily mean that the liver is free of steatosis, inflammation, or fibrosis. Conversely, elevated enzymes may have many causes other than fatty liver disease. Results must be interpreted alongside medical history, alcohol intake, medications, metabolic risks, and other testing.

How Fatty Liver Disease Is Diagnosed

Diagnosis usually begins with a medical history, physical examination, blood testing, and imaging. Clinicians also consider other causes of liver disease, including viral hepatitis, autoimmune conditions, medication-related injury, iron disorders, and inherited disease.

Blood Tests

ALT and AST may rise when liver cells are irritated or injured, but they do not measure liver fat directly. Other values—such as bilirubin, alkaline phosphatase, albumin, platelet count, glucose, hemoglobin A1c, triglycerides, and cholesterol—help evaluate liver patterns, metabolic risk, and possible advanced disease.

Blood-based fibrosis scores can combine several routine results. One commonly used example is FIB-4, which incorporates age, AST, ALT, and platelet count. These tools do not make a complete diagnosis, but they can help identify who may need further fibrosis assessment.

Imaging

Ultrasound may suggest liver fat, although it is less sensitive when smaller amounts of fat are present and cannot reliably determine whether MASH is present. CT and MRI may also identify steatosis, while specialized MRI techniques can quantify liver fat more precisely.

Elastography estimates liver stiffness. Increased stiffness can suggest fibrosis, although inflammation, congestion, and technical factors may also affect results. Elastography is often used with blood-based scores to decide whether specialist evaluation is needed.

Liver Biopsy

A liver biopsy removes a small tissue sample for microscopic examination. It can distinguish simple steatosis from steatohepatitis and show the amount and pattern of fibrosis. Because biopsy is invasive and carries risks, it is generally reserved for cases in which the diagnosis remains uncertain or the result would meaningfully change treatment.

Can Fatty Liver Disease Be Prevented?

Not every case can be prevented. Genetics, medications, other diseases, and environmental conditions may contribute in ways that are not fully controllable. However, many metabolic risk factors can be improved, and early changes may reduce the chance of progression.

Maintain or Work Toward a Sustainable Weight

For people with overweight or obesity, gradual weight loss can reduce liver fat. Losing approximately 3% to 5% of body weight may improve steatosis, while greater sustained losses may be needed to improve inflammation and fibrosis. Rapid weight loss and malnutrition should be avoided because they may worsen liver injury.

Weight loss is not the only meaningful outcome. Improved blood sugar, blood pressure, fitness, sleep, and triglyceride levels can be beneficial even when changes on the scale are modest.

Choose an Eating Pattern That Supports Metabolic Health

A practical eating pattern emphasizes vegetables, fruit, legumes, whole grains, nuts, seeds, fish, unsaturated fats, and appropriate portions of other nutrient-dense foods. Reducing frequent intake of sugar-sweetened beverages, heavily processed snack foods, and excessive saturated fat can make energy intake and metabolic risk easier to manage.

A rigid “liver cleanse” is unnecessary. Juice fasts, supplement regimens, and severe food restrictions do not remove liver fat on demand and may provide inadequate protein, fiber, or essential nutrients.

Be Physically Active Consistently

Physical activity can improve insulin sensitivity and reduce liver fat even when it does not produce substantial weight loss. Aerobic activity, resistance training, and reduced sedentary time may all contribute. The most useful plan is one that accounts for mobility, cardiovascular health, current fitness, and the likelihood that the activity can be maintained.

Someone who has been inactive or has heart disease, diabetes complications, severe obesity, or another limiting condition should discuss a safe starting plan with a healthcare professional.

Manage Diabetes, Blood Pressure, and Cholesterol

MASLD is part of a wider cardiometabolic picture. Managing blood sugar, blood pressure, triglycerides, and cholesterol may reduce the forces driving liver injury while also lowering cardiovascular risk. Medication should not be withheld simply because it is processed by the liver; the relevant question is whether it is appropriate and safe for that individual.

Reduce Alcohol Exposure

Alcohol can add metabolic stress and liver injury to an organ that already contains excess fat. People with MASH, fibrosis, cirrhosis, or abnormal liver tests may be advised to avoid alcohol. Others should discuss their intake honestly with a clinician because risk depends on both the quantity and the condition of the liver.

Review Medications and Supplements

An up-to-date list should include prescriptions, over-the-counter medicines, herbal products, vitamins, bodybuilding products, and concentrated extracts. Some supplements marketed for liver cleansing have been associated with liver injury, and product labels do not always provide a complete picture of safety or purity.

How Fatty Liver Disease Is Treated

Treatment begins by identifying the cause, estimating fibrosis risk, and addressing metabolic and cardiovascular health. For many people with early MASLD, the main approach remains sustainable nutrition, physical activity, weight management when appropriate, and treatment of diabetes, high blood pressure, and lipid abnormalities.

People with alcohol-associated disease need a plan focused on reducing or stopping alcohol safely. Medication-related disease may require adjustment of the suspected drug under medical supervision. Advanced fibrosis or cirrhosis usually requires specialist management and monitoring for complications.

Prescription Treatment for Selected Patients

The treatment landscape has changed. In 2024, the FDA approved resmetirom, sold as Rezdiffra, alongside diet and exercise for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. The approval used the accelerated approval pathway, meaning continued approval may depend on confirmation of longer-term clinical benefit.

In 2025, the FDA approved semaglutide, sold as Wegovy, for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. This indication was also granted through accelerated approval, with an ongoing trial assessing whether improvements in inflammation and fibrosis translate into fewer major liver-related events.

These medicines are not intended as universal treatment for anyone with liver fat. Patient selection depends on fibrosis stage, other health conditions, medication interactions, contraindications, and the balance of potential benefits and harms. Lifestyle and cardiometabolic care remain part of treatment even when a medication is prescribed.

What Does Not Prevent Fatty Liver Disease?

Several popular strategies sound liver-focused but do not address the main causes of disease.

Detox Drinks and Cleanses

A cleanse does not extract stored fat from liver cells or reverse fibrosis within a few days. The liver already processes chemicals continuously. Prevention depends on reducing ongoing metabolic and toxic stress, not temporarily replacing meals with juices or teas.

Extreme Fasting

Severe or prolonged food restriction may produce rapid weight loss and inadequate nutrition. Both can worsen liver health in some circumstances. Gradual change is safer and more likely to be maintained.

Relying Only on Liver Enzymes

ALT and AST are useful but incomplete. A person may have meaningful fibrosis with liver-enzyme levels that are not dramatically elevated. Risk assessment should consider diabetes, age, platelet count, imaging, fibrosis scores, and other clinical information.

Assuming the Condition Only Affects People With Obesity

Obesity is an important risk factor, but it is not required. Genetics, visceral fat, diabetes, cholesterol abnormalities, alcohol, medications, and uncommon diseases can contribute in people across a range of body sizes.

When to Seek Medical Advice

Arrange a medical evaluation when:

• Liver enzymes remain abnormal
• Imaging reports fatty liver or liver enlargement
• Type 2 diabetes is present alongside liver concerns
• There is a family history of cirrhosis or liver cancer
• Alcohol intake may be affecting health
• A medication or supplement could be contributing
• Fatigue or upper-right abdominal discomfort persists
• Previous testing suggests fibrosis

Seek urgent medical attention for yellowing of the eyes or skin, vomiting blood, black stools, severe confusion, rapid abdominal swelling, fainting, marked drowsiness, or other signs of rapidly worsening illness. These symptoms are not typical of uncomplicated early fatty liver and may indicate advanced liver dysfunction or another emergency.

The Bottom Line

Fatty liver disease is not one uniform condition. It may result from metabolic dysfunction, alcohol, medicines, nutritional problems, genetic disease, or overlapping causes. Most people have few early symptoms, so the condition is often found through blood tests or imaging.

The most important clinical question is not simply whether fat is present. It is whether inflammation or fibrosis has developed and whether the underlying drivers are being controlled.

Prevention and early management focus on sustainable eating habits, regular movement, gradual weight reduction when appropriate, careful alcohol and medication use, and effective management of diabetes, blood pressure, and cholesterol. People with moderate-to-advanced fibrosis may also qualify for prescription treatment under specialist guidance.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases — “Definition & Facts of NAFLD & NASH.” Overview of liver-fat accumulation, steatosis, inflammatory disease, cirrhosis, and liver-cancer risk.
2. National Institute of Diabetes and Digestive and Kidney Diseases — “Symptoms & Causes of NAFLD & NASH.” Explanation of symptoms, metabolic and genetic influences, alcohol-associated disease, medication-related causes, and nutritional causes.
3. European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity — Clinical Practice Guidelines on MASLD. Evidence-based recommendations covering terminology, prevention, risk assessment, diagnosis, and management.
4. American Association for the Study of Liver Diseases — “New MASLD Nomenclature.” Description of SLD, MASLD, MASH, MetALD, and the cardiometabolic framework used in the updated terminology.
5. U.S. Food and Drug Administration — Approval of Rezdiffra for liver scarring due to MASH/NASH. Regulatory information on resmetirom for selected adults with noncirrhotic disease and moderate-to-advanced fibrosis.
6. U.S. Food and Drug Administration — Approval of Wegovy for MASH. Regulatory information on semaglutide for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis.